Federal rules for allocating billions of dollars in scientific research may soon change, spurring concern among physicians that those alterations may derail the basic science that underlies biomedical discovery. In particular, by shifting funding authority from a merit-based, peer-reviewed system to unilateral decisions by political appointees of the current US government, physicians are warning that the funding revisions could imperil the future of healthcare.
From Peer Review to Political Review
In May 2026, the Office of Management and Budget (OMB) proposed a change to its guidance for federal financial assistance, or Uniform Guidance, a directive that would transform how agencies like the National Institutes of Health and the National Science Foundation distribute research grants.
Currently, an independent panel of science professionals evaluates grant applications based on merit. However, the proposed rule would require a political appointee to conduct a “pre-issuance review” to determine whether the proposal aligns with administration priorities and satisfies a new compliance standard OMB calls “Gold Standard Science.”
That standard—a set of principles outlined in a 2025 executive order that the agency claims are based in transparency and reproducibility—would take precedence, and peer review would be limited to an advisory capacity.
Physicians Raise Concerns
The proposed revisions have incited responses from a wide array of interested parties, from researchers and physicians to policymakers and professional societies.
While there is broad consensus that research funding should be transparent and accountable to American taxpayers, opinions differ regarding how merit should be balanced with administrative agendas.
In a statement, the American College of Physicians voiced that the proposal could “hinder our nation's ability to advance scientific discovery…making discoveries inaccessible to the clinicians, health systems, researchers, and policymakers responsible for improving patient care.”
For clinicians, their concerns extend deeper than how these rule changes will affect the broader medical and scientific communities; they worry about the long-term impact on their patients and their healthcare.
Investing in Miracles
For Jeffrey Saffitz, a physician-scientist and cardiac pathologist at Beth Israel Deaconess Medical Center who has spent much of his career conducting federally funded research, scientific discovery is a process built upon investigation and investment.
“The United States is preeminent in discovery, in biotech, in new products, and technology because we have invested taxpayer money,” he said. “We have developed a merit-based system where it doesn't matter who you are, where you come from, where you live, and what you do if you have the best idea.”
As an example of the medical advances that can come from this merit-based system, Saffitz referenced a profound case of cardiac amyloidosis he recognized in an autopsy. The disease arises when misfolded proteins accumulate in and stiffen the heart. The disease was once “a really dismal prognosis,” he added, “as bad as any cancer you could imagine.”
However, fundamental research that modeled the structure of the misfolded protein—instead of relying on trial-and-error compound screening—led to new drugs that can prevent or slow the disease's progression.
“It's been…a miracle,” he said. “People who would have been dead are now doing fine.” Saffitz is concerned that potentially politically targeted research will miss such opportunities to make the foundational discoveries on which those successes rely.
Saffitz is also worried that the rule change will have unintended consequences on the broader field of medical science.
“The money for supporting young scientific trainees is really drying up,” he said. “What's going to happen to those people? They're going to leave the system. They're going to go to other countries. They're going to maybe switch their careers…It’s not clear.”
Bench-to-Bedside
Joseph Freeman is an emergency-medicine physician who sees patients in rural communities throughout the southern United States. In his four-decade career, he too has witnessed the beneficial impacts of basic science research in the clinic, in particular for HIV treatment.
“When I first started practicing, HIV was essentially a death sentence,” he said. However, with advances in biomedical research, “It's [now] a chronic disease, as is hypertension, diabetes…any of the chronic diseases that people can live with.”
For Freeman, the proposal's looming ramifications, and the effects on his patients, are evident.
“When you cut research,” he explained, “there's a whole chain of consequences…Medicine is based on science, and science is based on humanity.” What starts as a discovery in the lab can then be produced into a medicine that a doctor prescribes for a patient. “But that provider has to be willing to understand that [drug development] part and give it some humanity…to bring it to the human level.”
What Happens Next
Though the time for public comments on this rule change closed on July 13, 2026, many voices continue to advocate against the changes.
Advocacy organizations such as the National Association of Counties and Stand Up for Science are taking direct action, with the latter preparing for litigation. Others are asking Congress to intervene before the rule's targeted October 1 roll-out date. At the time of this publication, the US Senate passed a funding bill that temporarily blocks the proposed revisions to the federal grant funding until December 11, 2026. However, the House version of the bill does not contain this delay and will need to be reconciled with the Senate version.
The success of such efforts will determine if peer review remains the deciding voice in research funding.
